Compare ADMA Biologics Inc (ADMA) vs TotalEnergies SE (TTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs TotalEnergies SE — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while TotalEnergies SE trades at $78.7 (market cap $171.68B). The key difference: TotalEnergies SE is far larger — about 80.6× ADMA Biologics Inc's market cap, and TotalEnergies SE pays a 5.41% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TTE | |
|---|---|---|
Market Cap | $2.13B | $171.68B |
Sector | Health | Energy |
52-Week High | $20.38 | $93.60 |
52-Week Low | $7.60 | $57.39 |
Enterprise Value | $2.20B | $205.82B |
Dividend Yield | — | 5.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TotalEnergies (TTE) trades at $77.96, up 1.66% with a bearish technical signal despite recent earnings beat. The stock shows attractive valuation with P/E of 11.32 and P/S of 0.91, supported by stable dividends. Revenue declined to $182.34B in 2025 but net margins improved to 8.2%. Recent developments include new exploration contracts and strategic divestments, while cash flow trends show recovery with 2026 projection of $2.9B net cash flow.
Outlook remains cautiously optimistic given strong analyst buy ratings (57.58%) and value metrics, though bearish technicals and revenue declines pose near-term risks. The company's strategic moves in gas fields and emissions technology provide growth avenues, but regulatory pressures and oil price volatility require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
